Published in BMJ Open on August 09, 2016
Letter to the Editor. Eur Clin Respir J (2017) 0.75
Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol (1994) 9.50
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Omalizumab for asthma in adults and children. Cochrane Database Syst Rev (2014) 2.13
Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum (2006) 1.85
Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol (1989) 1.60
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med (2006) 1.58
Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med (2010) 1.42
"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med (2009) 1.32
The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med (2009) 1.21
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis (2010) 1.17
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol (2007) 1.14
Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med (2009) 1.09
Italian real-life experience of omalizumab. Respir Med (2010) 1.06
Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma (2013) 1.02
Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med (2012) 1.01
Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess (2013) 1.01
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med (2014) 0.99
Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol (2013) 0.90
Types, frequency and impact of asthma triggers on patients' lives: a quantitative study in five European countries. J Asthma (2013) 0.84
Assessing the risk of attack in the management of asthma: a review and proposal for revision of the current control-centred paradigm. Prim Care Respir J (2013) 0.82
The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Int J Clin Pharm (2014) 0.81
Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma (2012) 0.79
Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting. Biol Ther (2014) 0.78